MAP Pharmaceuticals

Allergan and MAP: Pharma Buyout With a 60% Premium

Allergan and MAP: Pharma Buyout With a 60% Premium

Motley Fool

Allergan's Healthy Prospects

Allergan's Healthy Prospects

TheStreet.com

This Week in Biotech: Part 2

This Week in Biotech: Part 2

Motley Fool

Which Biotech Company Will Be Bought Out Next?

Which Biotech Company Will Be Bought Out Next?

Motley Fool

3 Biotech Stocks Surging Higher With Volume

3 Biotech Stocks Surging Higher With Volume

Seeking Alpha

FDA Decision On MAP's Levadex Approaching, Stock Starting To Reflect Optimism

FDA Decision On MAP's Levadex Approaching, Stock Starting To Reflect Optimism

Seeking Alpha

9 Pharmaceutical Stocks to Sell Now

9 Pharmaceutical Stocks to Sell Now

InvestorPlace

Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short Covering

Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short Covering

Seeking Alpha

This Week in Biotech

This Week in Biotech

Motley Fool

MAP Pharma's Awkward FDA Silence

MAP Pharma's Awkward FDA Silence

TheStreet.com